Oral Mucositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Oral Mucositis Pipeline Drugs Market Report Overview
Oral mucositis pipeline market research report provides comprehensive information on the therapeutics under development for oral mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects.
Key Targets in the Oral Mucositis Pipeline Market
The key targets in the oral mucositis pipeline market are Alpha Adrenergic Receptor, Bacterial Cell Membrane, Beta Adrenergic Receptor, Dihydrofolate Reductase, Endothelial PAS Domain Containing Protein 1, Fibroblast Growth Factor Receptor 1, and Fibroblast Growth Factor Receptor 2.
Key MoA in the Oral Mucositis Pipeline Market
The key MoA in the oral mucositis pipeline market are Alpha Adrenergic Receptor Agonist, Bacterial Cell Membrane Disruptor, Beta Adrenergic Receptor Agonist, Dihydrofolate Reductase Inhibitor, Endothelial PAS Domain Containing Protein 1 Inhibitor, Fibroblast Growth Factor Receptor 1 Agonist, and Fibroblast Growth Factor Receptor 2 Agonist.
Key RoA in the Oral Mucositis Pipeline Market
The key RoA in the oral mucositis pipeline market are intravenous, oral, topical, and ophthalmic. Oral has the highest number of pipeline products.
Oral Mucositis Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Oral Mucositis Pipeline Market
The key molecule types in the oral mucositis pipeline market are small molecule and recombinant protein.
Oral Mucositis Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Oral Mucositis Pipeline Market
The key companies in the oral mucositis pipeline market are MitoImmune Therapeutics Inc, Spectrum Pharmaceuticals Inc, Allander Biotechnologies LLC, Clevexel Pharma SA, Connext Co Ltd, Destiny Pharma Plc, GlycoMira Therapeutics Inc, Lakewood-Amedex Inc, Matrix Biomed Inc, Moberg Pharma AB, and VasoDynamics Ltd. MitoImmune Therapeutics Inc has the highest number of pipeline products.
Oral Mucositis Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
Key targets | Alpha Adrenergic Receptor, Bacterial Cell Membrane, Beta Adrenergic Receptor, Dihydrofolate Reductase, Endothelial PAS Domain Containing Protein 1, Fibroblast Growth Factor Receptor 1, and Fibroblast Growth Factor Receptor 2 |
Key MoA | Alpha Adrenergic Receptor Agonist, Bacterial Cell Membrane Disruptor, Beta Adrenergic Receptor Agonist, Dihydrofolate Reductase Inhibitor, Endothelial PAS Domain Containing Protein 1 Inhibitor, Fibroblast Growth Factor Receptor 1 Agonist, and Fibroblast Growth Factor Receptor 2 Agonist |
Key RoA | Intravenous, Oral, Topical, and Ophthalmic |
Key molecule types | Small Molecule and Recombinant Protein |
Key companies | MitoImmune Therapeutics Inc, Spectrum Pharmaceuticals Inc, Allander Biotechnologies LLC, Clevexel Pharma SA, Connext Co Ltd, Destiny Pharma Plc, GlycoMira Therapeutics Inc, Lakewood-Amedex Inc, Matrix Biomed Inc, Moberg Pharma AB, and VasoDynamics Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Clevexel Pharma SA
Connext Co Ltd
Destiny Pharma Plc
GlycoMira Therapeutics Inc
Lakewood-Amedex Inc
Matrix Biomed Inc
MitoImmune Therapeutics Inc
Moberg Pharma AB
Spectrum Pharmaceuticals Inc
VasoDynamics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the oral mucositis pipeline market?
The key targets in the oral mucositis pipeline market are Alpha Adrenergic Receptor, Bacterial Cell Membrane, Beta Adrenergic Receptor, Dihydrofolate Reductase, Endothelial PAS Domain Containing Protein 1, Fibroblast Growth Factor Receptor 1, and Fibroblast Growth Factor Receptor 2.
-
What are the key MoA in the oral mucositis pipeline market?
The key MoA in the oral mucositis pipeline market are Alpha Adrenergic Receptor Agonist, Bacterial Cell Membrane Disruptor, Beta Adrenergic Receptor Agonist, Dihydrofolate Reductase Inhibitor, Endothelial PAS Domain Containing Protein 1 Inhibitor, Fibroblast Growth Factor Receptor 1 Agonist, and Fibroblast Growth Factor Receptor 2 Agonist.
-
What are the key RoA in the oral mucositis pipeline market?
The key RoA in the oral mucositis pipeline market are intravenous, oral, topical, and ophthalmic.
-
What are the key molecule types in the oral mucositis pipeline market?
The key molecule types in the oral mucositis pipeline market are small molecule and recombinant protein.
-
What are the key companies in the oral mucositis pipeline market?
The key companies in the oral mucositis pipeline market are MitoImmune Therapeutics Inc, Spectrum Pharmaceuticals Inc, Allander Biotechnologies LLC, Clevexel Pharma SA, Connext Co Ltd, Destiny Pharma Plc, GlycoMira Therapeutics Inc, Lakewood-Amedex Inc, Matrix Biomed Inc, Moberg Pharma AB, and VasoDynamics Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.